Latent Tuberculosis Infection Screening Using QuantiFERON at Pre-Employment Assessment in Hospital Workers CHu Nice
September 1, 2026 updated by: Centre Hospitalier Universitaire de Nice
Relevance of Systematic Latent Tuberculosis Infection Screening Using QuantiFERON at Pre-Employment Assessment in Hospital Workers: A Retrospective Study at the University Hospital of Nice
This retrospective observational single-center study aims to evaluate the medical and occupational relevance of systematic screening for latent tuberculosis infection using QuantiFERON-TB Gold Plus during pre-employment occupational health assessment among hospital workers at the University Hospital of Nice.
Data will be collected retrospectively from occupational health medical records, immunology laboratory results and, when necessary, data from specialized follow-up by the tuberculosis control center.
The primary objective is to determine the proportion of positive QuantiFERON-TB Gold Plus tests at pre-employment screening.
Secondary objectives are to identify factors associated with a positive test, to describe the practical consequences of screening, including chest X-ray, diagnosis of latent tuberculosis infection and initiation of preventive treatment, and to estimate the cost of systematic screening.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
1185
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alpes Maritimes
-
Nice, Alpes Maritimes, France, 06000
- CHU de Nice
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
The study population consists of newly recruited hospital workers at the University Hospital of Nice who underwent pre-employment occupational health assessment and QuantiFERON-TB Gold Plus screening during the study period.
The population includes medical, paramedical, medico-technical, administrative, technical, logistical, transport and support staff, with or without direct patient contact.
Description
Inclusion Criteria:
- Newly recruited hospital workers at the University Hospital of Nice.
- Workers who underwent pre-employment occupational health assessment during the study period.
- Workers who had a QuantiFERON-TB Gold Plus test performed as part of pre-employment screening.
Exclusion Criteria:
- Incomplete or unusable occupational health records.
- Indeterminate QuantiFERON-TB Gold Plus results will be included in the descriptive analysis but excluded from comparative analyses of test positivity.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Hospital workers with direct patient contact
|
Retrospective analysis of QuantiFERON-TB Gold Plus results performed as part of routine pre-employment occupational health screening.
No additional diagnostic test or intervention will be performed for the purpose of the study.
|
|
Hospital workers without direct patient contact
|
Retrospective analysis of QuantiFERON-TB Gold Plus results performed as part of routine pre-employment occupational health screening.
No additional diagnostic test or intervention will be performed for the purpose of the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of positive QuantiFERON-TB Gold Plus tests at pre-employment screening
Time Frame: At the inclusion
|
Percentage of positive QuantiFERON-TB Gold Plus
|
At the inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Association between risk factors and positive QuantiFERON-TB Gold Plus test
Time Frame: At the inclusion
|
Variables collected included age, sex, country of birth, previous stay in a high tuberculosis-incidence area, prior contact with tuberculosis, immunosuppression status, occupational category, and direct patient contact
|
At the inclusion
|
|
Percentage of workers with clinical follow-up after positive QuantiFERON-TB Gold Plus test
Time Frame: From the positive QuantiFERON-TB Gold Plus test to completion of specialist follow-up.
|
Chest X-ray, referral to the tuberculosis control center or specialist consultation, final diagnosis of latent tuberculosis infection and initiation of preventive treatment.
|
From the positive QuantiFERON-TB Gold Plus test to completion of specialist follow-up.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2024
Primary Completion (Actual)
April 30, 2026
Study Completion (Actual)
April 30, 2026
Study Registration Dates
First Submitted
May 20, 2026
First Submitted That Met QC Criteria
May 20, 2026
First Posted (Actual)
May 27, 2026
Study Record Updates
Last Update Posted (Actual)
September 2, 2026
Last Update Submitted That Met QC Criteria
September 1, 2026
Last Verified
September 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 26SanteMentale01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.